Daewoong Pharma (069620 KO) stock market data APIs
₩129800
-200(-0.2%)
as of January 17, 2025
Daewoong Pharma Financial Data Overview
Price chart is built with
Anychart
Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Prev. Close
130000
Open
129800
Volume
22 562
High
131200
Low
128800
52 wk Range
100100-164400
Market Cap
1 495 819 M
Shares Outstanding
11 506 K
Revenue
1 399 052 M
EPS
2457.7744
Beta
0.774
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Daewoong Pharma data using free add-ons & libraries
Get Daewoong Pharma Fundamental Data
Daewoong Pharma Fundamental data includes:
- Net Revenue: 1 399 052 M
- EBITDA: 175 076 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-10-30
- EPS/Forecast: 2341
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daewoong Pharma News
New
Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis
SEOUL, South Korea, Jan. 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical's Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis (IPF), a ...
CGBio's 'NOVOSIS PUTTY' Receives FDA 'Breakthrough Device Designation,' Accelerate Entry into the US Market
The first Korean developed medical device for spine implantation Expecte to receive faster approval in the U.S. by priority support from the FDA NOVOSIS PUTTY, combining bone-forming proteins and cera...
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regul...
Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of NABOTA
High-dose Jeuveau, with a dosage double that of the existing 20 units, has succeeded in Phase 2 clinical trials as 'Extra Strength' Demonstrating a proven long-term efficacy of 6 months—double the t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
